多西紫杉醇联合奥沙利铂治疗复发性小细胞肺癌疗效观察

Clinical observation of Docetaxel combined with Oxapliplatin in the treatment of recurrence small cell lung cancer

目的 探讨多西紫杉醇联合奥沙利铂治疗复发性小细胞肺癌的疗效.方法 对60例病理证实为复发性小细胞肺癌患者给予多西紫杉醇联合奥沙利铂治疗,其中多西紫杉醇75mg/m2,分第1、8天静脉滴注,奥沙利铂130 mg/m2静脉滴注,第2天,每21天为1个周期.结果 总有效率为51.67％,完全缓解率为8.33％ （5/60）,部分缓解率为43.33％ （26/60）,稳定率为23.34％（14/60）,进展率为25％ （15/60）;中位疾病进展时间20周,中位生存期为28周,1年生存率为11.67％ （7/60）.不良反应主要为骨髓抑制,Ⅲ～Ⅳ度白细胞下降率为20％（12/60）,无粒细胞减少性发热,恶心、呕吐等消化道反应发生率为38.33％ （23/60）,但未见Ⅲ度消化道反应,50％ （30/60）患者有脱发,55％（33/60）患者出现外周神经毒性,但症状一般较轻且化疗结束后可自行好转,无严重肝、肾功能损害.无毒性相关死亡病例.结论 多西紫杉醇联合奥沙利铂治疗复发性小细胞肺癌近期疗效良好,不良反应轻,值得临床尝试和进一步研究.

Objective To investigate the effect of Docetaxel combined with Oxapliplatin on patients with recurrence small cell lung cancer.Methods Sixty patients with recurrence small cell lung cancer confimed pathologically were treated with intravenous infusion of Docetaxe 75 mg/m2 on d1,d8,Oxapliplatin 130 mg/m2 on d2.The chemotherapy cycles were repeated every 21 days.Results All the patients were available for response evaluation.The overall response rate was 51.67％,the complete remission rate was 8.33％,the partial remission rate was 43.33％,the stable rate was 23.34％,and the progression rate was 25％.The midian time to progression was 20 weeks,the median survival time was 28 weeks,and the rate of 1-year survival was 11.67％.The main adverse reaction was myelosuppression.Grade Ⅲ to Ⅳ leukopenia occurred in 20％ of the patients.There was no febrile neutropenia.Nausea and vomiting occurred in 38.33％ of the patients.The incidence of peripheral nerve toxicity was 55％,but it can relieve itself after stopping chemotherapy.There were no treatment-related death.Conclusions Docetaxel combined with Oxapliplatin in the treatment of patients with recurrence small cell lung cancer has good therapeutic effect,and with tolerable toxicity.